Photodynamic therapy in oncology

Oncologist

Volumn 11, Issue 9, 2006, Pages 1034-1044

  Triesscheijn, Martijn ^a   Baas, Paul ^a   Schellens, Jan H M ^a,b   Stewart, Fiona A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Aminolevulinic acid; mTHPC; Photodynamic therapy; Photofrin

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; LUTETIUM TEXAPHYRIN; MITOMYCIN C; MONO ASPARTYL CHLORIN E6; PHOTOFRIN; PHOTOSENSITIZING AGENT; SINGLET OXYGEN; TEMOPORFIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BARRETT ESOPHAGUS; BLADDER CANCER; BONE NECROSIS; BRONCHUS CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOUTH CANCER; NONHUMAN; PAIN; PHOTODERMATOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RED LIGHT; SKIN CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE; XEROSTOMIA;

HUMANS; LIGHT; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 33749854188     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-9-1034     Document Type: Article

References (118)

1. von Tappeiner H, Jesionek H. Therapeutische versuche mit fluoreszierenden stoffen. Munch Med Wochenschr 1903;47:2042-2044.
2. von Tappeiner HA, Jodlbauer A. Die Sensibilisierende Wirkung Fluorescierender Substanzen: Gesammelte Untersuchungen Über die Photodynamische Erscheinung. Leipzig, Germany: F.C.W. Vogel, 1907:1-210.
3. Dougherty TJ, Grindey GB, Fiel R et al. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975;55:115-121.
4. Dougherty TJ, Kaufman JE, Goldfarb A et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38:2628-2635.
5. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976;115:150-151.
6. Foote CS. Definition of type I and type II photosensitized oxidation. Photochem Photobiol 1991;54:659.
7. Henderson BW, Gollnick SO, Snyder JW et al. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004;64:2120-2126.
8. Morlet L, Vonarx-Coinsmann V, Lenz P et al. Correlation between meta (tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. Photochem Photobiol 1995;28:25-32.
9. Veenhuizen RB, Ruevekamp MC, Oppelaar H et al. Foscan-mediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies. Int J Cancer 1997;73:230-235.
10. Ris HB, Altermatt HJ, Stewart CM et al. Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer 1993;55:245-249.
11. Chen B, de Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett 2000;150:111-117.
12. Cramers P, Ruevekamp M, Oppelaar H et al. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 2003;88:283-290.
13. Triesscheijn M, Ruevekamp M, Aalders M et al. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem Photobiol 2005;81:1161-1167.
14. Veenhuizen R, Oppelaar H, Ruevekamp M et al. Does tumour uptake of Foscan determine PDT efficacy? Int J Cancer 1997;73:236-239.
15. Chen B, Pogue BW, Goodwin IA et al. Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res 2003;160:452-459.
16. Henderson BW, Waldow SM, Mang TS et al. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985;45:572-576.
17. Star WM, Marijnissen HPA, van den Berg-Blok AE et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986;46:2532-2540.
18. van Geel IP, Oppelaar H, Oussoren YG et al. Changes in perfusion of mouse tumours after photodynamic therapy. Int J Cancer 1994;56:224-228.
19. van Geel IP, Oppelaar H, Rijken PF et al. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br J Cancer 1996;73:288-293.
20. de Vree WJ, Essers MC, de Bruijn HS et al. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 1996;56:2908-2911.
21. Fingar VH, Siegel KA, Wieman TJ et al. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem Photobiol 1993;58:393-399.
22. Henderson BW, Sitnik-Busch TM, Vaughan LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol 1999;70:64-71.
23. Hendrzak-Henion JA, Knisely TL, Cincotta L et al. Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol 1999;69:575-581.
24. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999;137:91-98.
25. Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961;26:1-11.
26. el-Sharabasy MM, el-Waseef AM, Hafez MM et al. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992;65:409-412.
27. Divaris DX, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990;136:891-897.
28. Bourre L, Rousset N, Thibaut S et al. PDT effects of m-THPC and ALA, phototoxicity and apoptosis. Apoptosis 2002;7:221-230.
29. Ma L, Moan J, Berg K. Evaluation of a new photosensitizer, meso-tetrahydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 1994;57:883-888.
30. Rezzoug H, Barberi-Heyob M, Merlin JL et al. [In vitro comparison of the photodynamic activity of meso-tetra (m- hydroxyphenyl) chlorin and hematoporphyrin derivative.] Bull Cancer 1996;83:816-822. French.
31. van Geel IP, Oppelaar H, Oussoren YG et al. Photosensitizing efficacy of MTHPC-PDT compared to Photofrin-PDT in the RIF1 mouse tumour and normal skin. Int J Cancer 1995;60:388-394.
32. Yow CM, Chen JY, Mak NK et al. Cellular uptake, subcellular localization and photodamaging effect of temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative. Cancer Lett 2000;157:123-131.
33. Chan AL, Juarez M, Allen R et al. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces. Photodermatol Photoimmunol Photomed 2005;21:72-78.
34. Kaplan MJ, Somers RG, Greenberg RH et al. Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2). J Surg Oncol 1998;67:121-125.
35. Lui H, Hobbs L, Tope WD et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 2004;140:26-32.
36. Mang TS, Allison R, Hewson G et al. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am 1998;4:378-384.
37. Taber SW, Fingar VH, Coots CT et al. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clin Cancer Res 1998;4:2741-2746.
38. Kato H, Furukawa K, Sato M et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 2003;42:103-111.
39. Verigos K, Stripp DC, Mick R et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 2006;25:373-388.
40. van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy 1998;30:392-407.
41. Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 2004;40:372-382.
42. Kubler A, Niziol C, Sidhu M et al. [Analysis of cost effectiveness of photodynamic therapy with Foscan (Foscan-PDT) in comparison with palliative chemotherapy in patients with advanced head-neck tumors in Germany]. Laryngorhinootologie 2005;84:725-732. German.
43. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 2003;48:1273-1283.
44. Ris HB, Altermatt HJ, Inderbitzi R et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer 1991;64:1116-1120.
45. Grant WE, Speight PM, Hopper C et al. Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int J Cancer 1997;71:937-942.
46. Verrico AK, Haylett AK, Moore JV. In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy. Lasers Med Sci 2001;16:192-198.
47. Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer 1975;31:237-244.
48. Morales A. Treatment of superficial bladder cancer. Can Med Assoc J 1980;122:1133-1138.
49. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol 1984;2:83-116.
50. Rosenberg SJ, Williams RD. Photodynamic therapy of bladder carcinoma. Urol Clin North Am 1986;13:435-444.
51. Benson RC Jr. Laser photodynamic therapy for bladder cancer. Mayo Clin Proc 1986;61:859-864.
52. Nseyo UO, Dougherty TJ, Boyle DG et al. Whole bladder photodynamic therapy for transitional cell carcinoma of bladder. Urology 1985;26:274-280.
53. Nseyo UO, DeHaven J, Dougherty TJ et al. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg 1998;16:61-68.
54. Nseyo UO, Merrill DC, Lundahl SL. Green light photodynamic therapy in the human bladder. Clin Laser Mon 1993;11:247-250.
55. Waidelich R, Beyer W, Knuchel R et al. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source. Urology 2003;61:332-337.
56. Kriegmair M, Baumgartner R, Lumper W et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996;77:667-671.
57. Skyrme RJ, French AJ, Datta SN et al. A phase-1 study of sequential mitomycin C and 5-aminolaevulinic acid-mediated photodynamic therapy in recurrent superficial bladder carcinoma. BJU Int 2005;95:1206-1210.
58. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17-23.
59. Taub AF. Photodynamic therapy in dermatology: history and horizons. J Drugs Dermatol 2004;3(1 suppl):S8-S25.
60. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995;133:282-288.
61. Soler AM, Angell-Petersen E, Warloe T et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000;71:724-729.
62. Morton CA, Whitehurst C, Moseley H et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-771.
63. Morton CA, Whitehurst C, Moore JV et al. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000;143:767-772.
64. Salim A, Leman JA, McColl JH et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003;148:539-543.
65. Pagliaro J, Elliott T, Bulsara M et al. Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004;30:63-66.
66. Zeitouni NC, Shieh S, Oseroff AR. Laser and photodynamic therapy in the management of cutaneous malignancies. Clin Dermatol 2001;19:328-338.
67. Baas P, Saarnak AE, Oppelaar H et al. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol 2001;145:75-78.
68. Triesscheijn M, Ruevekamp M, Antonini N et al. Optimizing meso-tetrahydroxyphenyl-chlorin mediated photodynamic therapy for basal cell carcinoma. Photochem Photobiol (in press).
69. Copper MP, Tan IB, Oppelaar H et al. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2003;129:709-711.
70. Hopper C, Kubler A, Lewis H et al. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004;111:138-146.
71. Kubler AC, de Carpentier J, Hopper C et al. Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg 2001;30:504-509.
72. Schuller DE, McCaughan JS Jr, Rock RP. Photodynamic therapy in head and neck cancer. Arch Otolaryngol 1985;111:351-355.
73. Wile AG, Novotny J, Mason GR et al. Photoradiation therapy of head and neck cancer. Prog Clin Biol Res 1984;170:681-691.
74. Keller GS, Doiron DR, Fisher GU. Photodynamic therapy in otolaryngology - head and neck surgery. Arch Otolaryngol 1985;111:758-761.
75. Lou PJ, Jager HR, Jones L et al. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004;91:441-446.
76. Sihvo EI, Luostarinen ME, Salo JA. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 2004;99:419-424.
77. McCaughan JS Jr, Hicks W, Laufman L et al. Palliation of esophageal malignancy with photoradiation therapy. Cancer 1984;54:2905-2910.
78. Moghissi K, Dixon K, Thorpe JA et al. The role of photodynamic therapy (PDT) in inoperable oesophageal cancer. Eur J Cardiothorac Surg 2000;17:95-100.
79. Schweitzer VG, Bologna S, Batra SK. Photodynamic therapy for treatment of esophageal cancer: a preliminary report. Laryngoscope 1993;103:699-703.
80. Okunaka T, Kato H, Conaka C et al. Photodynamic therapy of esophageal carcinoma. Surg Endosc 1990;4:150-153.
81. Sibille A, Lambert R, Souquet JC et al. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995;108:337-344.
82. Grosjean P, Savary JF, Mizeret J et al. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin. J Clin Laser Med Surg 1996;14:281-287.
83. Overholt BF, Panjehpour M, DeNovo RC et al. Photodynamic therapy for esophageal cancer using a 180 degrees windowed esophageal balloon. Lasers Surg Med 1994;14:27-33.
84. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-256.
85. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-498.
86. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7.
87. Panjehpour M, Overholt BF, Haydek JM et al. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 2000;95:2177-2184.
88. Wolfsen HC. Carpe luz - seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest Endosc 2005;62:499-503.
89. Pacifico RJ, Wang KK, Wongkeesong LM et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003;1:252-257.
90. Ackroyd R, Brown NJ, Stephenson TJ et al. Ablation treatment for Barrett oesophagus: what depth of tissue destruction is needed? J Clin Pathol 1999;52:509-512.
91. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-188.
92. Gossner L, Stolte M, Sroka R et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-455.
93. Ortner MA, Zumbusch K, Liebetruth J et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy 2002;34:611-616.
94. Ackroyd R, Brown NJ, Davis MF et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612-617.
95. Ackroyd R, Kelty CJ, Brown NJ et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 2003;35:496-501.
96. McCaughan JS Jr, Williams TE. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J Thorac Cardiovasc Surg 1997;114:940-946; discussion 946-947.
97. Kato H. Photodynamic therapy for lung cancer - a review of 19 years' experience. J Photochem Photobiol B 1998;42:96-99.
98. Diaz-Jimenez JP, Martinez-Ballarin JE, Llunell A et al. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J 1999;14:800-805.
99. Moghissi K, Dixon K, Stringer M et al. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 1999;15:1-6.
100. Furuse K, Fukuoka M, Kato H et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol 1993;11:1852-1857.
101. Imamura S, Kusunoki Y, Takifuji N et al. Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer. Cancer 1994;73:1608-1614.
102. Wiedmann M, Berr F, Schiefke I et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004;60:68-75.
103. Marks PV, Belchetz PE, Saxena A et al. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial - an early report. Br J Neurosurg 2000;14:317-325.
104. Hendren SK, Hahn SM, Spitz FR et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 2001;8:65-71.
105. Moore CM, Nathan TR, Lees WR et al. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg Med 2006;38:356-363.
106. Nathan TR, Whitelaw DE, Chang SC et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002;168:1427-1432.
107. Bown SG, Rogowska AZ, Whitelaw DE et al. Photodynamic therapy for cancer of the pancreas. Gut 2002;50:549-557.
108. Snyder JW, Greco WR, Bellnier DA et al. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res 2003;63:8126-8131.
109. Kirveliene V, Grazeliene G, Dabkeviciene D et al. Schedule-dependent interaction between doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo. Cancer Chemother Pharmacol 2006;57:65-72.
110. Baas P, van Geel IP, Oppelaar H et al. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br J Cancer 1996;73:945-951.
111. Chen B, Ahmed B, Landuyt W et al. Potentiation of photodynamic therapy with hypericin by mitomycin C in the radiation-induced fibrosarcoma-1 mouse tumor model. Photochem Photobiol 2003;78:278-282.
112. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002;62:1604-1608.
113. Jalili A, Makowski M, Switaj T et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 2004;10:4498-4508.
114. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006;55:900-909.
115. Dimitroff CJ, Klohs W, Sharma A et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999;17:121-135.
116. Zhou Q, Olivo M, Lye KY et al. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 2005;56:569-577.
117. Ferrario A, Fisher AM, Rucker N et al. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res 2005;65:9473-9478.
118. Ferrario A, Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 2006;25:251-260.